Steven Grossman argues that the former commissioner possessed the credentials to be out front on the pricing issue, unlike other recent FDA commissioners and the current holder of the office.
Scott Gottlieb’s skill set may have facilitated a new, but likely temporary, foray by the US Food and Drug Administration into the drug pricing arena as his follower does not possess the same qualifications to lead on the issue.
Agency stakeholders were surprised when Gottlieb became commissioner in 2017 calling for a more active FDA role lowering drug prices....
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
